Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“Sacituzumab tirumotecan approved for a second indication by NMPA in China:
for the treatment of adult patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor therapy and platinum-based chemotherapy.”
